BioStem Technologies, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BSEM research report →
About the company
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use.
- CEO
- Jason Matuszewski
- IPO
- 2015
- HQ
- Fort Lauderdale, FL, US
Price Chart
- Market Cap
- $55.03M
- P/E
- -2.75
- P/S
- -2.91
- P/B
- 1.71
- EV/EBITDA
- -3.16
- Div Yield
- 0.00%
- Gross Margin
- 128.16%
- Op Margin
- 78.38%
- Net Margin
- 105.15%
- ROE
- -47.03%
- ROIC
- -42.17%
- Revenue
- $47.48M · -84.27%
- Net Income
- $-6,580,912 · -120.64%
- EPS
- $-0.39 · -120.00%
- Op Income
- $-689,147
- FCF YoY
- -72.60%
- 52W High
- $12.65
- 52W Low
- $3.09
- 50D MA
- $4.11
- 200D MA
- $4.70
- Beta
- 0.21
- Avg Volume
- 59.65K
Get TickerSpark's AI analysis on BSEM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BSEM coverage
Recent articles, reports, and earnings notes.
No research on BSEM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BSEM report →Similar companies
Peers in the same neighborhood.